Rein Therapeutics (NASDAQ:RNTX) Shares Down 0.8% – Should You Sell?

Rein Therapeutics Inc. (NASDAQ:RNTX)’s share price was down 0.8% during trading on Thursday . The company traded as low as $1.22 and last traded at $1.22. Approximately 52,502 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 237,899 shares. The stock had previously closed at $1.23.

Wall Street Analysts Forecast Growth

RNTX has been the topic of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. HC Wainwright assumed coverage on Rein Therapeutics in a report on Monday, September 22nd. They set a “buy” rating and a $10.00 price target on the stock. Brookline Capital Management raised Rein Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 3rd. Finally, Loop Capital set a $6.00 target price on Rein Therapeutics in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Trading Down 0.8%

The business has a 50 day moving average price of $1.39 and a 200-day moving average price of $1.33. The firm has a market capitalization of $32.07 million, a PE ratio of -0.46 and a beta of 1.31.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. On average, equities research analysts forecast that Rein Therapeutics Inc. will post -1.56 earnings per share for the current year.

Insider Activity

In related news, major shareholder Voss Capital, Lp acquired 178,392 shares of Rein Therapeutics stock in a transaction that occurred on Tuesday, October 28th. The stock was purchased at an average price of $1.39 per share, for a total transaction of $247,964.88. Following the completion of the purchase, the insider directly owned 500,000 shares of the company’s stock, valued at approximately $695,000. This trade represents a 55.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have bought 410,233 shares of company stock valued at $550,563. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Gleason Group Inc. acquired a new stake in shares of Rein Therapeutics during the 3rd quarter valued at approximately $26,000. Blair William & Co. IL purchased a new position in Rein Therapeutics in the 2nd quarter valued at approximately $33,000. Meridian Wealth Advisors LLC acquired a new position in Rein Therapeutics during the second quarter worth $40,000. Exencial Wealth Advisors LLC purchased a new stake in Rein Therapeutics during the second quarter worth $43,000. Finally, Susquehanna International Group LLP acquired a new stake in Rein Therapeutics in the third quarter valued at $35,000. 90.89% of the stock is owned by hedge funds and other institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.